A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in participants with type 2 diabetes, cardiovascular risk factors, and moderate to severely impaired renal function.
Inclusion criteria :
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Caba, 1120, Argentina
Caba, C1093AAS, Argentina
Caba, C1118AAE, Argentina
Caba, C1119ACN, Argentina
Caba, C1128AAF, Argentina
Caba, Argentina
Capital Federal, C1056ABJ, Argentina
Capital Federal, C1179AAB, Argentina
Ciudad Autonoma de Bs.As, C1428DCO, Argentina
Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
Western Cape, 7130, South Africa
Vinnitsya, 21018, Ukraine
Vinnitsya, 21100, Ukraine
Davyhulme, Manchester, M41 5SL, United Kingdom